Fundraising FoxIntervene Immune
Manhattan Beach, US · Nevada corporation
Find your way into Intervene Immune
Sign up to see every warm intro you have to Intervene Immune
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Intervene Immune team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Intervene Immune develops treatments aimed at rejuvenating the immune system by regenerating the thymus and reversing biological aging, building on its TRIIM and TRIIM-X clinical trials. The company applies aging biology and epigenetic age measurement to human longevity interventions.
Founders & leadership
GF
Greg FahyChief Scientific OfficerGreg Fahy is a cryobiologist and biogerontologist who has published clinical trials on immune system rejuvenation and epigenetic age reversal, including the TRIIM and TRIIM-X studies; he has also conducted research on organ cryopreservation by vitrification and authored work on biological aging mechanisms.
PK
Philip Kernan Jr.Named on SEC filing
Reported raises · per SEC filings
Form D private placements$470.8K disclosed across 1 round · 2013
▶$470.8KraisedDec 2019 · 6 investors · BiotechnologyRule 506(b)
▶$470.8KraisedDec 2019 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregory FahyExecutive Officer, Director
- Robert BrookeExecutive Officer, Director
- Philip Kernan Jr.Executive Officer, Director
- Paul HynekExecutive Officer
- Amount sold
- $470.8K
- First sale
- Nov 2013
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 04, 06b, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
VerImmuneVerImmune develops immunotherapy medicines that redirect pre-existing immune memory toward cancer cells to achieve tumor destruction with low toxicity. The company targets cancer patients across a broad range of cancer types.
InimmuneInimmune is a clinical-stage biotech company developing immunotherapies for allergy, cancer, infectious, and autoimmune diseases. The company combines immunology and vaccine expertise to advance its clinical and pre-clinical pipeline.
Immunomic TherapeuticsImmunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.
EvolveImmune TherapeuticsEvolveImmune develops immunotherapy treatments for cancer patients. The company focuses on discovering and developing novel biotherapeutics in immuno-oncology and related immune-mediated diseases.
Companies working in the same space as Intervene Immune.
Frequently asked questions
- What does Intervene Immune do?
- Intervene Immune develops treatments aimed at rejuvenating the immune system by regenerating the thymus and reversing biological aging, building on its TRIIM and TRIIM-X clinical trials. The company applies aging biology and epigenetic age measurement to human longevity interventions.
- Who founded Intervene Immune?
- Intervene Immune was founded by Robert Brooke, Greg Fahy.
- How much funding has Intervene Immune raised?
- Intervene Immune has disclosed $470.8K raised across 1 round.
- Where is Intervene Immune headquartered?
- Intervene Immune is headquartered in Manhattan Beach, US.